Please Gilead, Celgene and Amgen. Don’t Buy Medivation.
May 26, 2016 at 10:33 AM EDT
RBC's Michael Yee and team writes that a Medivation ( MDVN ) purchase "may not be [the] best value creation" for large cap biotech stocks Amgen ( AMGN ), Gilead Sciences ( GILD ) and Celgene ( CELG ). They explain why:
